ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 02/17/22

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear ce...

Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022. An Emergency Use Authorization of Sotrovimab has been filed as an intramuscular injection for patients with mi...

Image source: The Motley Fool. Arrowhead Pharmaceuticals (NASDAQ: ARWR) Q1 2022 Earnings Call Feb 02, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Arrowhead Pharmaceuticals (ARWR) Q1 2022 Earnings Call Transcript...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2022 Results Conference Call February 02, 2022 04:30 PM ET Company Participants Vince Anzalone - VP, IR Dr. Christopher Anzalone - President and CEO Dr. Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO Dr. James Hamilton - SVP, Discovery...

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) are down 4% in after-hours trading amid a significant miss on EPS in its FQ1 2022 results and a huge miss on revenue. The company reported GAAP EPS in the quarter of -$0.60, a $0.20 miss. Revenue of $27.4M missed by $23.6M. Arrowhead...

Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q1 GAAP EPS of -$0.60 misses by $0.20. Revenue of $27.4M (+28.6% Y/Y) misses by $23.64M. For further details see: Arrowhead Pharmaceuticals GAAP EPS of -$0.60 misses by $0.20, revenue of $27.4M misses by $23.64M

- Conference Call and Webcast Today, February 2, 2022 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021. The company is hosting a conference call today, February 2, 2022, at 4:30 ...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some volatility in January as I start converting conservative investments into riskier assets after big Fed based sell-offs. Making monthly contributions, even though they seem small at the time, makes...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (LSE/NYSE: GSK) announced on November 22, 2021, has now closed. Closing of the transaction was subject to customary closing conditions and expiration ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021. Conference Call and Webcast Details ...